title: Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis.
abstract: BACKGROUND
  Although early trials indicate the treatment of restenosis with radiation therapy is safe and effective, the long-term impact of this new technology has been questioned. The possibility of late untoward consequences, such as aneurysm formation, perforation, and accelerated vascular disease, is of significant concern. Furthermore, it is not known whether the beneficial effects of radiation therapy will be durable or whether radiation will only delay restenosis.
  
  
  RESULTS
  A double-blind, randomized trial was undertaken to compare 192Ir with placebo sources in patients with previous restenosis after coronary angioplasty. Patients were randomly assigned to receive a 0.76-mm (0. 03-in) ribbon containing sealed sources of either 192Ir or placebo. All patients underwent repeat coronary angiography at 6 months. All living patients were contacted 24 months after their index study procedure. Patients were assessed with respect to the need for target-lesion revascularization or nontarget-lesion revascularization, occurrence of myocardial infarction, or death. Over a 9-month period, 55 patients were enrolled; 26 were randomized to 192Ir and 29 to placebo. Follow-up was obtained in 100% of living patients at a minimum of 24 months. Target-lesion revascularization was significantly lower in the 192Ir group (15.4% versus 44.8%; P<0. 01). Nontarget-lesion revascularization was similar in 192Ir and placebo patients (19.2% versus 20.7%; P=NS). There were 2 deaths in each group. The composite end point of death, myocardial infarction, or target-lesion revascularization was significantly lower in 192Ir-treated versus placebo-treated patients (23.1% versus 51.7%; P=0.03). No patient in the 192Ir group sustained a target-lesion revascularization later than 10 months.
  
  
  CONCLUSIONS
  At 2-year clinical follow-up, treatment with 192Ir demonstrates significant clinical benefit. Although further follow-up (including late angiography) will be necessary, no clinical events have occurred to date in the 192Ir group to suggest major untoward effects of vascular radiotherapy. At the intermediate follow-up time point, vascular radiotherapy continues to be a promising new treatment for restenosis.
authors.affiliation: Division of Cardiovascular Diseases, and the Division of Radiation Oncology, Scripps Clinic, La Jolla, CA, USA.
authors.forename: P S
authors.initials: PS
authors.lastname: Teirstein
authors.forename: V
authors.initials: V
authors.lastname: Massullo
authors.forename: S
authors.initials: S
authors.lastname: Jani
authors.forename: R J
authors.initials: RJ
authors.lastname: Russo
authors.forename: D A
authors.initials: DA
authors.lastname: Cloutier
authors.forename: R A
authors.initials: RA
authors.lastname: Schatz
authors.forename: E M
authors.initials: EM
authors.lastname: Guarneri
authors.forename: S
authors.initials: S
authors.lastname: Steuterman
authors.forename: K
authors.initials: K
authors.lastname: Sirkin
authors.forename: S
authors.initials: S
authors.lastname: Norman
authors.forename: P
authors.initials: P
authors.lastname: Tripuraneni
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D002404:Catheterization; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D007495:Iridium / Q000008:administration & dosage; D009204:Myocardial Revascularization / Q000379:methods*; D012008:Recurrence
chemical_list: D007495:Iridium